Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares, rose in value, with the stock price down by -1.43% to the previous day’s close as strong demand from buyers drove the stock to $1.38.
Actively observing the price movement in the last trading, the stock closed the session at $1.40. The value of beta (5-year monthly) was 2.39. Referring to stock’s 52-week performance, its high was $2.05, and the low was $0.42. On the whole, ADAP has fluctuated by -6.76% over the past month.
With the market capitalization of Adaptimmune Therapeutics Plc ADR currently standing at about $313.49 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.1, which is expected to increase to -$0.01 for fiscal year -$0.27 and then to about -$0.37 by fiscal year 2025. Data indicates that the EPS growth is expected to be 50.00% in 2025, while the next year’s EPS growth is forecast to be -37.00%.
According to the average forecast, sales growth in current quarter could jump down -88.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $70.04 million, representing an increase of 16.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ADAP’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ADAP currently trading nearly -8.61% and 4.49% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.41, while the 7-day volatility ratio is showing 7.56% which for the 30-day chart, stands at 11.48%. Furthermore, Adaptimmune Therapeutics Plc ADR (ADAP)’s beta value is 2.40, and its average true range (ATR) is 0.15.
A comparison of Adaptimmune Therapeutics Plc ADR (ADAP) with its peers suggests the former has fared considerably weaker in the market. ADAP showed an intraday change of -1.43% in last session, and over the past year, it grew by 26.61%%.
Data on historical trading for Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) indicates that the trading volumes over the past 10 days have averaged 1.28 million and over the past 3 months, they’ve averaged 1.89 million. According to company’s latest data on outstanding shares, there are 227.17 million shares outstanding.
Nearly 1.98% of Adaptimmune Therapeutics Plc ADR’s shares belong to company insiders and institutional investors own 62.39% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.11 million shares as on Mar 15, 2024, resulting in a short ratio of 1.55. According to the data, the short interest in Adaptimmune Therapeutics Plc ADR (ADAP) stood at 1.26% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 2.93 million. The stock has risen by 74.02% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ADAP stock heading into the next quarter.
